Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers
在HER2阴性晚期胃癌中,多西他赛-奥沙利铂-卡培他滨/5-氟尿嘧啶(DOX/F)序贯多西他赛与奥沙利铂-卡培他滨/5-氟尿嘧啶(CAPOX/FOLFOX)的疗效比较
期刊:JNCI Cancer Spectrum
影响因子:4.1
doi:10.1093/jncics/pkae054
Ramaswamy, Anant; Bhargava, Prabhat; Dubashi, Biswajit; Gupta, Anuj; Kapoor, Akhil; Srinivas, Sujay; Shetty, Omshree; Jadhav, Poonam; Desai, Veena; Noronha, Vanita; Joshi, Amit; Menon, Nandini; Patil, Vijay M; Mishra, Bal Krishna; Sansar, Bipinesh; Singh, Arpita; Patel, Swapnil; Singh, Satyendra Narayan; Dhal, Ipsita; Vinayak, Kunal Ranjan; Pal, Vikash; Mandavkar, Sarika; Kannan, Sadhana; Chaugule, Deepali; Patil, Rajshree; Parulekar, Manali; Nashikkar, Chaitali; Ankathi, Suman Kumar; Kaushal, Rajiv Kumar; Shah, Aekta; Ganesan, Prasanth; Kayal, Smita; Ananthakrishnan, Ramesh; Syed, Noorzia; Samaddar, Debdeep; Kapu, Venkatesh; Shah, Anokhi; Kaaviya, D; Suganiya, R; Srinivasan, Nirmala Devi; Prabhash, Kumar; Ostwal, Vikas